DAFNA Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

DAFNA Capital Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,204,825	Closed	-$5.37M	–	91
2021 Q1	$5.37M	Buy	+1,204,825	New	+$5.61M	1.28%	22
2015 Q4	–	Sell	-119,319	Closed	-$1.41M	–	82
2015 Q3	$1.41M	Sell	119,319 -3,760	-3%	-$59.8K	1.4%	21
2015 Q2	$2.4M	Hold	123,079	–	–	2.03%	18
2015 Q1	$2.19M	Sell	123,079 -15,310	-11%	-$300K	1.68%	15
2014 Q4	$2.55M	Buy	138,389 +9,545	+7%	+$205K	2.01%	15
2014 Q3	$3.12M	Buy	128,844 +11,000	+9%	+$317K	3.14%	11
2014 Q2	$4.3M	Hold	117,844	–	–	4.08%	10
2014 Q1	$5.4M	Hold	117,844	–	–	4.64%	7
2013 Q4	$4.58M	Hold	117,844	–	–	4.72%	7
2013 Q3	$5.34M	Buy	117,844 +31,033	+36%	+$1.59M	5.83%	2
2013 Q2	$4.26M	Buy	+86,811	New	+$4.61M	6.24%	4

Other funds holding PLX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

DAFNA Capital Management's PLX Position: Q2 2021 in Review

DAFNA Capital Management sold out of Protalix BioTherapeutics (PLX) in Q2 2021, closing a stake of 1,204,825 shares — an estimated $5.37M sold.

DAFNA Capital Management first reported a position in PLX in Q2 2013 and held it in 11 quarters. The position peaked at $5.4M in Q1 2014. 33 funds tracked by Wall St. Rank hold PLX as of Q2 2021.

DAFNA Capital Management reported no remaining Protalix BioTherapeutics position as of Q2 2021 after selling out during the quarter.
DAFNA Capital Management sold 1,204,825 Protalix BioTherapeutics shares in Q2 2021, an estimated $5.37M.
DAFNA Capital Management first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 11 quarters.
DAFNA Capital Management's Protalix BioTherapeutics position peaked at $5.4M in Q1 2014.
33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2021.

Based on DAFNA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.